Crespo-Lessmann Astrid, Juárez-Rubio Cándido, Plaza-Moral Vicente
Servicio de Neumología, Hospital de Santa Creu i Sant Pau, Barcelona, España.
Arch Bronconeumol. 2010 Mar;46(3):135-42. doi: 10.1016/j.arbres.2009.07.011. Epub 2009 Sep 17.
There has been growing interest in the last 10 years in the study of innate immunity, in particular because of the possible role that toll-like receptors (TLR) may play in the pathogenesis of some respiratory diseases including, asthma, chronic obstructive pulmonary disease, and infections. TLR are a family of type 1 transmembrane proteins, responsible for recognising molecular patterns associated with pathogens (PAMP, pathogen-associated molecular patterns), and expressed by a broad spectrum of infectious agents. This recognition leads to a quick production of cytokines and chemokines which provides a long-lasting adaptive response to the pathogen. At present, it is considered //It is currently considered that the administration of drugs which modulate the activity of these receptors upwards or downwards may represent major therapeutic progress for handling these diseases. The aim of this review is to describe the different TLS, define their possible role in the pathogenesis of the main respiratory diseases and finally, speculate over the therapeutic possibilities which their modulation, agonist or antagonist, offers as possible therapeutic targets.
在过去十年中,对固有免疫的研究兴趣日益浓厚,特别是由于Toll样受体(TLR)在包括哮喘、慢性阻塞性肺疾病和感染在内的一些呼吸道疾病发病机制中可能发挥的作用。TLR是一类1型跨膜蛋白家族,负责识别与病原体相关的分子模式(PAMP,病原体相关分子模式),并由多种感染因子表达。这种识别导致细胞因子和趋化因子的快速产生,从而对病原体产生持久的适应性反应。目前,人们认为上调或下调这些受体活性的药物给药可能代表着治疗这些疾病的重大治疗进展。本综述的目的是描述不同的TLS,确定它们在主要呼吸道疾病发病机制中的可能作用,最后推测其激动剂或拮抗剂调节作为可能治疗靶点所提供的治疗可能性。